As the new CP variants identified in N. edaphicum CCNP1411 inhibited the activity of trypsin or chymotrypsin at low concentrations and were inactive against the other tested enzymes and MCF-7 breast cancer cells, their possible use as therapeutic agents should be further explored. Here, CP is linked to breast carcinoma.